Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab?

0
Posted

Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab?

0

We congratulate Bonner and colleagues for their updated 5-year survival analysis of radiotherapy plus cetuximab for locoregionally advanced head and neck cancer.1 Regrettably, the authors have chosen not to update the primary endpoint, locoregional control, which makes it more difficult for the readers to interpret the study.

Related Questions

Thanksgiving questions

*Sadly, we had to bring back ads too. Hopefully more targeted.